An analysis published in the journal BMJ Global Health on Tuesday found that the global eradication of COVID-19 is more feasible than it is for polio, but considerably less so than it was for smallpox.
It has been noted by the public health experts from the University of Otago Wellington in New Zealand that vaccination, public health measures, and global interest in achieving this goal all make eradication of COVID-19 possible. The authors calculated the feasibility of coronavirus eradication that is defined as ‘the permanent reduction to zero of the worldwide incidences of infection caused by a specific agent as a result of deliberate efforts’.
They however said that the major challenge falls in securing sufficiently high vaccine coverage and respond quickly enough to immune-escape variants of SARS-CoV-2, the virus that causes COVID-19. They further compared it with the two other viral scourges for which vaccines were or are available for smallpox and polio — using an array of technical, sociopolitical, and economic factors that are likely to help achieve this goal. The authors of the study used a three-point scoring system for each of 17 variables which are:
- the availability of a safe and effective vaccine
- lifelong immunity, impact of public health measures, and
- effective government management of infection control messaging among others.
The authors wrote in the study, “While our analysis is a preliminary effort, with various subjective components, it does seem to put COVID-19 eradicability into the realms of being possible, especially in terms of technical feasibility.”
The average scores in the analysis added up to 2.7 for smallpox, 1.6 for COVID-19, and 1.5 for polio, they said. Smallpox was declared eradicated in 1980 and two out of the three serotypes of poliovirus have also been eradicated globally.
They acknowledge that relative to smallpox and polio, the technical challenges of COVID-19 eradication include poor vaccine acceptance, and the emergence of more highly transmissible variants that may evade immunity, potentially outrunning global vaccination programmes.
The authors explained, “Nevertheless, there are of course limits to viral evolution, so we can expect the virus to eventually reach peak fitness, and new vaccines can be formulated.”
“Other challenges would be the high upfront costs for vaccination and upgrading health systems, and achieving the necessary international cooperation in the face of ‘vaccine nationalism’ and government-mediated ‘antiscience aggression’,” they added.
The persistence of the virus in animal reservoirs may also prevent eradication efforts suggests the researchers, however, this does not appear to be a serious issue. It has also been noted by the researchers that there is a global will to attack the infection.
The massive scale of the health, social and economic impacts of coronavirus across the world has generated, the authors said “unprecedented global interest in disease control and massive investment in vaccination against the pandemic.”
“Collectively these factors might mean that an ‘expected value’ analysis could ultimately estimate that the benefits outweigh the costs, even if eradication takes many years and has a significant risk of failure,” the authors added.
They said, unlike smallpox and polio, COVID-19 also benefits from the added impact of public health measures, such as border controls, social distancing, contact tracing and mask wearing, which can be very effective if deployed well.